|Bid||27.00 x 1900|
|Ask||27.64 x 2000|
|Day's Range||27.06 - 27.83|
|52 Week Range||10.04 - 32.50|
|PE Ratio (TTM)||137.22|
|Earnings Date||Nov 1, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||32.29|
The FDA approved Gilead's Yescarta for DLBCL, second CAR-T therapy in the United States. The regulatory authority also granted priority review to label expansion applications for four major cancer drugs.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Exelixis, Inc. Here are 5 ETFs with the largest exposure to EXEL-US. Comparing the performance and risk of Exelixis, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
NEW YORK, NY / ACCESSWIRE / October 19, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies, is issuing a comprehensive ...
Exelixis, Inc. announced today that its third quarter 2017 financial results will be released on Wednesday, November 1, 2017 after the markets close. At 5:00 p.m. EDT / 2:00 p.m.
LONDON, UK / ACCESSWIRE / October 18, 2017 / Pro-Trader Daily looks at the latest corporate events and news making the headlines for Exelixis, Inc. (NASDAQ: EXEL ), following which we have published a ...
Key highlights include regulatory updates from Exelixis (EXEL) and Spark Therapeutics and pipeline updates from Regeneron and Ionis among others.
Exelixis (EXEL) announced that the FDA has granted priority review to its supplemental New Drug Application (sNDA) for kidney cancer drug Cabomteyx.
NEW YORK, NY / ACCESSWIRE / October 17, 2017 / Dynavax saw some gains on Monday, though there was no major catalyst to explain the small and modest pop. Earlier in the month shares had broken out over ...
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Exelixis, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)
On another record day for major benchmarks, Exelixis soared on news about its cancer drug, and PG&E sank on concerns about a potential role in the California fires.
Exelixis popped early Monday after the FDA granted its drug, Cabometyx, priority review to treat advanced kidney cancer.
Stocks that moved substantially or traded heavily Monday: Aramark, up 20 cents to $42.53 The food, facilities and uniform company agreed to make two acquisitions for $2.35 billion. Tesla Inc., down $4.97 ...
The South San Francisco, Calif.-based company said Oct. 16 its Phase 3 study of cabozantinib achieved its primary endpoint of overall survival in patients that have advanced hepatocellular carcinoma.
Exelixis kicked off the week with a couple updates that are already having a big impact on the stock. These updates came in the form of a key FDA approval.
Shares of biotech Exelixis Inc. rallied 19% in premarket trade Monday, after the company said it has won U.S. Food and Drug Administration priority review status for its supplemental New Drug Application ...
Exelixis Inc said on Monday its drug met the main goal in a late stage study for treating patients with a type of liver cancer. The drug, Cabometyx, showed statistically significant improvement in overall ...
Exelixis, Inc. today announced that the U.S. Food and Drug Administration has determined the company’s supplemental New Drug Application for CABOMETYX® for patients with previously untreated advanced renal cell carcinoma to be sufficiently complete to permit a substantive review.
Exelixis, Inc. today announced that its global phase 3 CELESTIAL trial met its primary endpoint of overall survival , with cabozantinib providing a statistically significant and clinically meaningful improvement in median OS compared to placebo in patients with advanced hepatocellular carcinoma .